Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Equity (2017 - 2025)

Protagonist Therapeutics' Return on Equity history spans 9 years, with the latest figure at 0.21% for Q4 2025.

  • For Q4 2025, Return on Equity fell 66.0% year-over-year to 0.21%; the TTM value through Dec 2025 reached 0.21%, down 66.0%, while the annual FY2025 figure was 0.2%, 75.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.21% at Protagonist Therapeutics, down from 0.07% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.46% in Q4 2024 and bottomed at 0.65% in Q1 2023.
  • The 5-year median for Return on Equity is 0.01% (2021), against an average of 0.06%.
  • The largest annual shift saw Return on Equity skyrocketed 110bps in 2021 before it plummeted -66bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then tumbled by -71063bps to 0.55% in 2022, then soared by 57bps to 0.24% in 2023, then surged by 290bps to 0.46% in 2024, then plummeted by -145bps to 0.21% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Return on Equity are 0.21% (Q4 2025), 0.07% (Q3 2025), and 0.08% (Q2 2025).